Nucleic acid-based drug for corneal opacities
Project/Area Number |
26462680
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Ophthalmology
|
Research Institution | The University of Tokyo |
Principal Investigator |
USUI TOMOHIKO 東京大学, 医学部附属病院, 准教授 (80282557)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 角膜 / 核酸医薬 / 血管新生 |
Outline of Final Research Achievements |
Nucleic acid drug is expected as new therapeutic tool for various diseases because of its high safety and economical aspects. Recently, we generate a single-stranded proline-modified short hairpin ribonucleric acid interference (RNAi) and micro-RNA (mi-RNA) molecule that is carried in a lipid nano-particle for topical application. This agent can penetrate all layers of the cornea and successfully inhibit the expressions of target molecules. This modified nucleic acid agent will be a new topical formulation for use against corneal diseases.
|
Report
(4 results)
Research Products
(6 results)
-
-
-
-
-
[Presentation] 角膜の透明性を守る為に2015
Author(s)
臼井智彦
Organizer
第119回日本眼科学会総会
Place of Presentation
札幌
Year and Date
2015-04-15 – 2015-04-19
Related Report
Invited
-